MedPath
TGA Approval

KYNTELES vedolizumab (rch) 300 mg powder for injection vial (210042)

210042

KYNTELES vedolizumab (rch) 300 mg powder for injection vial

Takeda Pharmaceuticals Australia Pty Ltd

June 27, 2014

Medicine

Medicine

Active

Registered

Active Ingredients

vedolizumab

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.